| Id |
Subject |
Object |
Predicate |
Lexical cue |
| p1_all0 |
0-49 |
Intervention |
denotes |
DVP01 "Inactivated mycobacteria bead preparation" |
| p2_i0 |
0-56 |
Pharmacological |
denotes |
DVP01 "Inactivated mycobacteria bead preparation" method |
| p1_all1 |
262-291 |
Population |
denotes |
patients with cystic fibrosis |
| p1_all2 |
1095-1131 |
Population |
denotes |
immunocompromised and senior people. |
| p1_all3 |
1561-1611 |
Intervention |
denotes |
standard ethanol/formic acid extraction procedure. |
| p1_all4 |
1827-1839 |
Outcome |
denotes |
Mass spectra |
| p1_all5 |
2161-2200 |
Intervention |
denotes |
standard ethanol/formic acid extraction |
| p1_all6 |
2288-2311 |
Outcome |
denotes |
quality of mass spectra |
| p2_o12 |
2288-2311 |
Other |
denotes |
quality of mass spectra |
| p1_all7 |
2476-2501 |
Outcome |
denotes |
good quality mass spectra |
| p2_o13 |
2476-2501 |
Other |
denotes |
good quality mass spectra |
| p1_all8 |
2520-2536 |
Outcome |
denotes |
average quality. |
| p1_all9 |
2894-2906 |
Outcome |
denotes |
Mass spectra |
| p1_all10 |
2952-2968 |
Outcome |
denotes |
peak intensities |
| p1_all11 |
4348-4358 |
Intervention |
denotes |
Ampicillin |
| p2_i1 |
4348-4358 |
Pharmacological |
denotes |
Ampicillin |
| p1_all12 |
4752-4776 |
Outcome |
denotes |
Inhibition of hydrolysis |
| p1_all13 |
4855-4892 |
Outcome |
denotes |
MS spectrum corresponding to DH5alpha |
| p1_all14 |
4924-4934 |
Intervention |
denotes |
Ampicillin |
| p1_all15 |
5205-5234 |
Outcome |
denotes |
slight spontaneous hydrolysis |
| p2_o37 |
5205-5234 |
Physical |
denotes |
slight spontaneous hydrolysis |
| p1_all16 |
5281-5327 |
Outcome |
denotes |
Successful inhibition of Ampicillin hydrolysis |
| p2_o38 |
5281-5327 |
Physical |
denotes |
Successful inhibition of Ampicillin hydrolysis |
| p1_all17 |
5747-5796 |
Outcome |
denotes |
disappearance of the molecular peak of Ertapenem. |
| p1_all18 |
5812-5822 |
Intervention |
denotes |
Ampicillin |
| p2_i2 |
5812-5822 |
Pharmacological |
denotes |
Ampicillin |
| p1_all19 |
5947-5974 |
Outcome |
denotes |
molecular peak of Ertapenem |
| p1_all20 |
6321-6356 |
Outcome |
denotes |
beta-lactamase activity of bacteria |
| p1_all21 |
6522-6556 |
Population |
denotes |
patients with cystic fibrosis (CF) |
| p1_all22 |
6560-6624 |
Intervention |
denotes |
repetitive sequence-based PCR (rep-PCR) using DiversiLab System. |
| p1_all23 |
6634-6648 |
Intervention |
denotes |
Sputum samples |
| p1_all24 |
6649-6677 |
Population |
denotes |
(n=623) from 165 CF patients |
| p1_all25 |
6731-6758 |
Outcome |
denotes |
isolation of S. maltophilia |
| p1_all26 |
6929-6943 |
Population |
denotes |
33 CF patients |
| p1_all27 |
7616-7642 |
Outcome |
denotes |
rate of genetic diversity. |
| p2_o56 |
7849-7867 |
Physical |
denotes |
molecular profiles |
| p1_all28 |
7990-8002 |
Population |
denotes |
CF patients. |
| p2_i3 |
8322-8350 |
Pharmacological |
denotes |
5-Iodonaphthyl 1-azide (INA) |
| p1_all29 |
8322-8391 |
Intervention |
denotes |
5-Iodonaphthyl 1-azide (INA) and amotosalen (AMO, also known as S-59) |
| p1_all30 |
8478-8561 |
Intervention |
denotes |
Vaccinia virus (VacV), an orthopox virus with a DNA genome, and Pixuna virus (PIXV) |
| p2_i4 |
8630-8639 |
Pharmacological |
denotes |
UVA alone |
| p1_all31 |
8630-8676 |
Intervention |
denotes |
UVA alone or when exposed to either INA or AMO |
| p1_all32 |
9332-9365 |
Intervention |
denotes |
tox-encoded diphtheria toxin (DT) |
| p2_i5 |
9332-9365 |
Pharmacological |
denotes |
tox-encoded diphtheria toxin (DT) |
| p1_all33 |
11293-11299 |
Intervention |
denotes |
OXA-48 |
| p2_i6 |
11293-11299 |
Pharmacological |
denotes |
OXA-48 |
| p1_all34 |
11310-11317 |
Intervention |
denotes |
OXA-162 |
| p2_i7 |
11310-11317 |
Pharmacological |
denotes |
OXA-162 |
| p1_all35 |
11327-11332 |
Intervention |
denotes |
KPC-2 |
| p1_all36 |
11343-11348 |
Intervention |
denotes |
KPC-3 |
| p1_all37 |
11405-11410 |
Outcome |
denotes |
NDM-1 |
| p1_all38 |
11442-11508 |
Outcome |
denotes |
included.The sensitivity of the MHT on Mueller-Hinton agar (Oxoid) |
| p1_all39 |
11918-11946 |
Outcome |
denotes |
sensitivity of the MBL Etest |
| p1_all40 |
12399-12403 |
Intervention |
denotes |
EDTA |
| p1_all41 |
12473-12503 |
Outcome |
denotes |
Urinary tract infections (UTI) |
| p1_all42 |
13102-13183 |
Population |
denotes |
inpatients sent to the Institute for Medical Microbiology for routine diagnostic. |
| p1_all43 |
13460-13485 |
Intervention |
denotes |
2.5-dihydroxybenzoic acid |
| p1_all44 |
14357-14385 |
Population |
denotes |
humans and domestic animals. |
| p2_i8 |
15137-15365 |
Physical |
denotes |
high-salt DNA isolation protocol (PeqLab, Germany) b) MagBeads DNA extraction protocol (Carl-Roth, Germany) c) column-based DNA extraction protocol (PeqLab, Germany) and d) a modified TriPure-isolation protocol (PeqLab, Germany) |
| p1_all45 |
15137-15366 |
Intervention |
denotes |
high-salt DNA isolation protocol (PeqLab, Germany) b) MagBeads DNA extraction protocol (Carl-Roth, Germany) c) column-based DNA extraction protocol (PeqLab, Germany) and d) a modified TriPure-isolation protocol (PeqLab, Germany). |
| p1_all46 |
15621-15685 |
Intervention |
denotes |
liquid nitrogen or f) without pre-treatment prior DNA isolation. |
| p1_all47 |
16177-16253 |
Intervention |
denotes |
proteinase k overnight combined with an additional liquid nitrogen treatment |
| p1_all48 |
16265-16285 |
Outcome |
denotes |
highest DNA recovery |
| p1_all49 |
16722-16747 |
Outcome |
denotes |
quantity of isolated DNA. |
| p1_all50 |
16906-16934 |
Intervention |
denotes |
-lactamases-producing (ESBL) |
| p1_all51 |
17057-17095 |
Outcome |
denotes |
minimal inhibitory concentration (MIC) |
| p1_all52 |
17360-17466 |
Population |
denotes |
Program 1378 E. coli from diseased food-delivering and companion animals were collected from 2006 to 2007. |
| p1_all53 |
17467-17764 |
Intervention |
denotes |
MIC determination by broth microdilution to -lactam-antibiotics (penicillin G, cefotaxime, cefoperazone, cefquinome, ceftiofur), and disk diffusion confirmatory test for ESBL (ceftazidine (30μg)/ ceftazidine-clavulanic acid (30μg/10μg) and cefotaxime (30μg)/ cefotaxime-clavulanic acid (30μg/10μg) |
| p2_i9 |
17511-17556 |
Pharmacological |
denotes |
-lactam-antibiotics (penicillin G, cefotaxime |
| p2_i10 |
17558-17594 |
Pharmacological |
denotes |
cefoperazone, cefquinome, ceftiofur) |
| p2_i11 |
17707-17717 |
Pharmacological |
denotes |
cefotaxime |
| p1_all54 |
17819-17861 |
Intervention |
denotes |
Brilliance ESBL ® chromogenic agar (Oxoid) |
| p2_o125 |
17959-18017 |
Other |
denotes |
detection of blaCTX-M-, blaOXA-, blaTEM-, and blaSHV-genes |
| p1_all55 |
18089-18099 |
Outcome |
denotes |
MIC values |
| p2_o126 |
18089-18099 |
Physical |
denotes |
MIC values |
| p2_i12 |
18114-18124 |
Pharmacological |
denotes |
cefotaxime |
| p1_all56 |
18438-18448 |
Intervention |
denotes |
cefotaxime |
| p2_i13 |
18438-18448 |
Pharmacological |
denotes |
cefotaxime |
| p1_all57 |
18839-18883 |
Outcome |
denotes |
disk diffusion test one falsepositive strain |
| p1_all58 |
19386-19406 |
Intervention |
denotes |
Rapid isolate typing |
| p2_i14 |
19386-19406 |
Physical |
denotes |
Rapid isolate typing |
| p1_all59 |
19755-19778 |
Intervention |
denotes |
imipenem and meropenem. |
| p1_all60 |
19779-19803 |
Outcome |
denotes |
Carbapenemase production |
| p1_all61 |
21119-21130 |
Intervention |
denotes |
PFGE, MLST) |
| p2_o149 |
21137-21180 |
Other |
denotes |
ease of applicability and low running costs |
